COMP <GO>
ANIP vs UNH // RETURN ON INVESTED CAPITAL (ROIC)
ANI Pharmaceuticals Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: ANIP 7
— UNH 5
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ANIP
LAST: $70.67 (-1.85%) • MKT CAP: $1.62B
roic
16.00%
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
roic
12.38%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ANIP VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ANIP | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.31% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 16.00% | 12.38% | +3.62 | ANIP | /roic <GO> |
| EV/EBITDA & P/E Valuation | 13.7x | 15.3x | -1.57 | ANIP | /valuation <GO> |
| Free Cash Flow Yield | 10.20% | 6.25% | +3.95 | ANIP | /fcf-yield <GO> |
| Operating Margin | 12.60% | 5.32% | +7.28 | ANIP | /operating-margins <GO> |
| Net Profit Margin | 8.80% | 3.53% | +5.27 | ANIP | /net-margins <GO> |
| Revenue Growth (YoY) | 43.80% | 3.33% | +40.47 | ANIP | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.07% | 2.29% | -2.22 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.36 | 3.09 | -0.73 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | ANIP | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.9 | 55.1 | -12.20 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.1x | 17.7x | +0.36 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.62B | $359.43B | -$357.81B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ANIP REV | UNH REV | ANIP GROSS % | UNH GROSS % | ANIP FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $883.4M | $447.57B | — | 88.7% | $171.4M | $16.07B |
| FY 2024 | $614.4M | $400.28B | — | 88.3% | $47.8M | $20.70B |
| FY 2023 | $486.8M | $371.62B | — | 89.6% | $119.0M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ANIP // BETA —
UNH // BETA 0.33